Oncoinvent raises $16M to fuel ovarian cancer trial readout
What's the deal? Norwegian biotech Oncoinvent has raised US$18M in a private placement and retail offering, co-led by Linc ABDealroom has a profile for this one. Try Dealroom → and Hadean VenturesDealroom has a profile for this one. Try Dealroom →. The company allocated 1,650,000 new shares at a fixed price of US$10.9 each.
What does it do? Oncoinvent develops alpha radiation therapy for patients whose cancer has spread to the abdominal cavity — a group with few treatment options and high relapse risk. Its lead program targets ovarian cancer.
Who's backing it? Existing top shareholders anchored the round: Linc took shares worth roughly US$2.1M, and Hadean Ventures, which sits on the board, about US$2.09M. The private placement made up US$16.7M; the retail portion, run through Nordnet Bank ABDealroom has a profile for this one. Try Dealroom →, added US$1.29M.
What's the money for? The proceeds fund a more mature Phase 2 interim readout in ovarian cancer, expected in March or April 2027, based on close to all patients. The company also plans to complete Phase 2 recruitment in the first half of 2027 and pursue regulatory alignment with the US Food and Drug Administration and the European Medicines Agency ahead of Phase 3 submissions.
Why now? The raise extends Oncoinvent's cash runway into the second half of 2027, past the interim readout. "This financing lets us base a Phase 2 interim readout in ovarian cancer on a larger, more mature dataset, and push ahead with Phase 3 preparations," said chief executive officer Øystein Soug.
What's the endgame? A stronger dataset positions the company for Phase 3. "A more robust dataset gives Oncoinvent the strongest possible foundation for its next phase," said board chair Gillies O'Bryan-Tear, adding the company now has "funding now secured beyond this milestone."
The signal: The round sits in the lower-mid range for its category, reflecting a targeted, milestone-driven raise rather than a broad war chest. For clinical-stage biotechs, tying capital to a specific data readout is a familiar way to de-risk the next, larger round.
Read more: placera.se
Image credit: National Institutes of Health (NIH)
